www.klinickafarmakologie.cz / Klin Farmakol Farm 2022;36(4):129-135 / KLINICKÁ FARMAKOLOGIE A FARMACIE 135 HLAVNÍ TÉMA Význam terapeutického monitorování léčiv při optimalizaci dávkování acykloviru LITERATURA 1. Majewska A, Mlynarczyk-Bonikowska B. 40 years after the registration of acyclovir: Do we need new anti-herpetic drugs? Int J Mol Sci. 2022;23(7):3431. 2. Nishii R, Mizuno T, Rehling D, et al. NUDT15 polymorphism influences the metabolism and therapeutic effects of acyclovir and ganciclovir. Nat Commun. 2021;12(1):4181. 3. Brandariz-Nuñez D, Correas-Sanahuja M, Maya-Gallego S, et al. Neurotoxicity associated with acyclovir and valacyclovir: A systematic review of cases. J Clin Pharm Ther. 2021;46(4):918-926. 4. Abuhelwa Z, Beran A, Venkataramany BS, et al. https://pubmed.ncbi.nlm.nih.gov/35509998/ – affiliation-1 Concurrent nephrotoxicity and neurotoxicity induced by oral valacyclovir in a patient with previously normal kidney function. Cureus. 2022;14(3):e23693. 5. Kacirova I, Urinovska R, Sagan J. Therapeutic monitoring of serum concentrations of acyclovir and its metabolite 9-(carboxymethoxymethyl) guanine in routine clinical practice. Biomed Pharmacother. 2022;156:113852. 6. Ärlemalm A, Helldén A, Karlsson L, et al. Rapid determination of acyclovir, its main metabolite 9-carboxymethoxymethylguanine, ganciclovir, and penciclovir in human serum using LC-MS/MS. Biomed Chromatogr. 2022;36(4):e5315. 7. Sadjadi SA, Regmi S, Chau T. Acyclovir neurotoxicity in a peritoneal dialysis patient: Report of a case and review of the pharmacokinetics of acyclovir. Am J Case Rep. 2018;19:1459-1462. 8. Maximova N, Nisticò D, Luci G, et al. Population pharmacokinetics of intravenous acyclovir in oncologic pediatric patients. Front Pharmacol. 2022;13:865871. 9. Gunness P, Aleksa K, Bend J, et al. Acyclovir-induced nephrotoxicity: the role of the acyclovir aldehyde metabolite. Transl Res. 2011;158(5):290-301. 10. Al-Alawi AM, Al-Maqbali JS, Al-Adawi M, et al. Incidence, patterns, risk factors and clinical outcomes of intravenous acyclovir induced nephrotoxicity. Saudi Pharm J. 2022;30(6):874-877. 11. Helldén A, Odar-Cederlöf I, Larsson K, et al. Death delusion. BMJ. 2007;335(7633):1305. 12. Helldén A, Odar-Cederlöf I, Diener P, et al. High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanine in renal failure patients with acyclovir-related neuropsychiatric side effects: an observational study. Nephrol Dial Transplant 2003;18:1135-1141. 13. Helldén A, Lycke J, Vander T, et al. The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment. J Antimicrob Chemother. 2006;57(5):945-949. 14. Cotard J. Du délire des négations. Arch Neurol 1882;4:152170, 282-296. 15. Robertson KM, Harvey CL, Cunningham JM. Acyclovir- -induced neurotoxicity with a positive cerebrospinal fluid varicella zoster PCR result creating a management dilemma: a case report. J Med Case Rep. 2020;14(1):156. 16. Abdalla S, Briand C, Oualha M, et al. Population pharmacokinetics of intravenous and oral acyclovir and oral valacyclovir in pediatric population to optimize dosing regimens. Antimicrob Agents Chemother. 2020;64(12):e01426-20. 17. Abdul-Aziz MH, Alffenaar JWC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med. 2020;46(6):1127-1153. 18. Cies JJ, Moore WS, Miller K, et al. Therapeutic drug monitoring of continuous-infusion acylovir for disseminated herpes simplex virus infection in a neonate receiving concurrent extracorporeal life support and continuous renal replacement therapy. Pharmacotherapy. 2015;35(2):229-233. 19. Euler M, Axelsson G, Helldén A. Differential diagnosis of central nervous system involvement in a patient treated with acyclovir. Ther Drug Monit. 2013;35(4):417-419. 20. Lycke J, Andersen O, Svennerholm B, et al. Acyclovir concentrations in serum and cerebrospinal fluid at steady state. J Antimicrob Chemother. 1989;24(6):947-954. 21. Yang HH, Hsiao YP, Shih HC, et al. Acyclovir-induced neuropsychosis successfully recovered after immediate hemodialysis in an end-stage renal disease patient. Int J Dermatol. 2007;46(8):883-884. 22. Schulz M, Schmoldt A, Andresen-Streichert H, et al. Revisited: Therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics. Crit Care. 2020;24(1):195. 23. Feldman S, Rodman J, Gregory B. Excessive serum concentrations of acyclovir and neurotoxicity. J Infect Dis. 1988;157(2):385-388. 24. Urinovska R, Kacirova I, Sagan J. Determination of acyclovir and its metabolite 9-carboxymethoxymethylguanide in human serum by ultra-high-performance liquid chromatography-tandem mass spektrometry. J Sep Sci. 2021;44(16):3080-3088.
RkJQdWJsaXNoZXIy NDA4Mjc=